• Explore /
  • Poster
  • / Updated interim analysis of the randomized phase 1b/3 study of tazemetostat in combination with lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma.

Updated interim analysis of the randomized phase 1b/3 study of tazemetostat in combination with lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma.

Abstract Video & Slides Poster

Authors

null

Connie Lee Batlevi

Memorial Sloan Kettering Cancer Center, New York, NY

Connie Lee Batlevi , Steven I. Park , Tycel Jovelle Phillips , Jennifer Amengual , David Jacob Andorsky , Philip Campbell , Pamela McKay , John Paul Leonard , Manu Sondhi , Jay Yang , Yingxue Chen , Heather O'Connor , Pamela Slatcher , Franck Morschhauser

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Non-Hodgkin Lymphoma

Clinical Trial Registration Number

NCT04224493

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 7572)

DOI

10.1200/JCO.2022.40.16_suppl.7572

Abstract #

7572

Poster Bd #

224

Abstract Disclosures

Similar Posters

First Author: Marjorie Glass Zauderer

First Author: Andrew David Zelenetz

First Author: Susan N. Chi

First Author: Susan N. Chi